What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Florence Vorspan,Peter Hjelmström,Nicolas Simon,Amine Benyamina,Alain Dervaux,Georges Brousse,Thierry Jamain,Margaux Kosim,Benjamin Rolland +8 more
Reads0
Chats0
TLDR
Buvidal® could constitute a promising treatment option mainly in case of: 1) OMT initiation, including in non-specialized addiction medicine care; 2) Discharge from prison or hospital; Diversion/misuse of 3) buprenorphine or 4) methadone; 5) Clinically stabilized patients wishing to avoid daily oral taking of the medication.Abstract:
Introduction: Since the 1990s, opioid maintenance treatments (OMTs), i.e. mostly methadone and buprenorphine, have represented the therapeutic cornerstone of opioid dependence. In France, the public health strategy on opioid dependence, identified here as the 'French model', has consisted of offering a facilitated access to buprenorphine, to reach a large treatment coverage and reduce opioid-related mortality. Areas covered: Recently, a new formulation of subcutaneous buprenorphine depot (Buvidal®) has been approved in Europe for treatment of opioid dependence. The place of Buvidal® among the pre-existing arsenal of OMTs is discussed in the light of the pharmacological specificities of this new formulation, and with the particular standpoint of the French model on opioid dependence. Expert opinion: Buvidal® could constitute a promising treatment option mainly in case of: 1) OMT initiation, including in non-specialized addiction medicine care; 2) Discharge from prison or hospital; Diversion/misuse of 3) buprenorphine or 4) methadone; 5) Clinically stabilized patients wishing to avoid daily oral taking of the medication. As such, this new formulation should be highly accessible, which will require specific pathways through care as the product is intended to be administered by a healthcare professional.read more
Citations
More filters
Journal ArticleDOI
[Prolonged-release buprenorphine formulations: Perspectives for clinical practice].
Mathieu Chappuy,Benoit Trojak,Philippe Nubukpo,Jérôme Bachellier,Patrick Bendimerad,Georges Brousse,Benjamin Rolland +6 more
TL;DR: While opioid users report some concerns with a risk of coercive use of long-acting forms of buprenorphine, both users and professionals deem that these new specialties could be particularly appreciated in stabilized patients bothered with the daily intake of the treatments, or specific situations at risk of treatment dropout.
Journal ArticleDOI
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Adrian Dunlop,Bethany White,Jillian Roberts,Michelle Cretikos,Dena Attalla,Rod Ling,Andrew Searles,Judith Mackson,Michael Doyle,Elizabeth McEntyre,John Attia,John Attia,Christopher Oldmeadow,Mark V. Howard,Terry Murrell,Paul S. Haber,Nicholas Lintzeris +16 more
TL;DR: In this paper, the safety of subcutaneous slow-release depot buprenorphine in custodial settings was assessed by adverse event (AE) monitoring and physical examinations at every visit.
Journal ArticleDOI
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update.
TL;DR: Clinical data available so far on the efficacy of these 3 medications are given, and possible clinical implications are discussed.
Journal ArticleDOI
Long-acting depot buprenorphine in people who are homeless: Views and experiences.
TL;DR: This article explored the views of people who are homeless and dependent on prescribed or illicit opiates/opioids on the range of ORT delivery options, including long-acting buprenorphine (LAB) depot injection, methadone liquid, and sublingual/wafer bupregine.
Journal ArticleDOI
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Benjamin Rolland,Benoit Trojak,Mikail Nourredine,Jérôme Bachellier,Mathieu Chappuy,Patrick Bendimerad,Margaux Kosim,Peter Hjelmström,Fadi Meroueh,Philippe Nubukpo,Georges Brousse +10 more
TL;DR: In this article, the authors explored the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.
References
More filters
Journal ArticleDOI
Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017
TL;DR: More timely and comprehensive surveillance data are essential to inform efforts to prevent and respond to opioid overdoses; intensified prevention and response measures are urgently needed to curb deaths involving prescription and illicit opioids, specifically IMF.
Journal ArticleDOI
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Luis Sordo,Luis Sordo,Gregorio Barrio,María J. Bravo,B. Iciar Indave,Louisa Degenhardt,Louisa Degenhardt,Lucas Wiessing,Marica Ferri,Roberto Pastor-Barriuso +9 more
TL;DR: Retention in methadone and buprenorphine treatment is associated with substantial reductions in the risk for all cause and overdose mortality in people dependent on opioids.
Journal ArticleDOI
A Medical Treatment for Diacetylmorphine (Heroin) Addiction: A Clinical Trial With Methadone Hydrochloride
Vincent P. Dole,Marie Nyswander +1 more
TL;DR: A group of 22 patients, previously addicted to diacetylmorphine (heroin), have been stabilized with oral methadone hydrochloride, and with this medication, patients have shown marked improvement; they have returned to school, obtained jobs, and have become reconciled with their families.
Journal ArticleDOI
Global Burden of Disease Attributable to Illicit Drug Use and Dependence: Findings From the Global Burden of Disease Study 2010
Louisa Degenhardt,Louisa Degenhardt,Harvey Whiteford,Harvey Whiteford,Alize J. Ferrari,Alize J. Ferrari,Amanda J Baxter,Amanda J Baxter,Fiona J Charlson,Fiona J Charlson,Wayne Hall,Greg Freedman,Roy Burstein,Nicole E. Johns,Rebecca E. Engell,Abraham D. Flaxman,Christopher J L Murray,Theo Vos +17 more
TL;DR: Efficient strategies to reduce disease burden of opioid dependence and injecting drug use, such as delivery of opioid substitution treatment and needle and syringe programmes, are needed to reduce this burden at a population scale.
Journal ArticleDOI
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Marc R. Larochelle,Dana Bernson,Thomas Land,Thomas J. Stopka,Na Wang,Ziming Xuan,Sarah M. Bagley,Jane M. Liebschutz,Alexander Y. Walley +8 more
TL;DR: In this paper, a multivariable Cox proportional hazards model was used to examine MOUD as a monthly time-varying exposure variable to predict time to all-cause and opioid-related mortality.
Related Papers (5)
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Barbara R. Haight,Susan M Learned,Céline M. Laffont,Paul J. Fudala,Y Zhao,Amanda S. Garofalo,Mark K. Greenwald,Vijay R Nadipelli,Walter Ling,Christian Heidbreder,James L. Andersen,Genie L. Bailey,Scott Robert Bartley,Michael J. Biunno,Brent Boyett,Jesse M. Carr,Eduardo Cifuentes,Sandra Daniela Duarte-Sckell,Otto R. Dueno,Boyde J. Harrison,David R. Hassman,Kent Steven Hoffman,Valentin Isacesu,Saleem Ishaque,Rishi Kakar,Kyle M. Kampman,Richard D. Knapp,George Konis,Jelena Kunovac,Joseph A. Kwentus,Lawrence S. Levinson,Shishuka Malhotra,Vishaal Mehra,Ricky Stuart Mofsen,Marvin Lane Peyton,Gita G. Pujari,Rakesh Ranjan,Daniel Rutrick,Gregory Seal,Scott Daniel Segal,Rajinder Shiwach,Haydn Mikel Thomas,Peter Paul Ventre,Amit K. Vijapura,David P. Walling,Katharina Wiest +45 more